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exposure (Wolffgramm and Heyne, 1995; Turyabahika-Thyen and 
Wolffgramm, 2006), repeated deprivation periods (Spanagel and 
Holter, 1999), ethanol vapor chamber approaches (Rimondini et al., 
2003) or severe withdrawal effects (Diana et al., 1993) to produce 
rats which are ‘dependent’ on ethanol. The disadvantage of these 
procedures is the considerable investment in time and the need for 
substantial animal facilities to house such large populations of rats 
for up to a year, something which is beyond the scope of most labo-
ratories. To overcome these difficulties, we approached the problem 
from a different angle. Rather than using chronic ethanol exposure 
to induce a prefrontal cortex dysfunction, our goal was to induce 
dysfunction first in order to determine whether this would affect 
the response to ethanol.
The schizophrenia field uses phencyclidine (PCP) to mimic the 
symptoms and cognitive deficits observed clinically in this condi-
tion (Allen and Young, 1978; Krystal et al., 1994). In recent years, 
studies have used repeated administration of PCP to induce chronic 
adaptations (Jentsch and Roth, 1999). Initially, the paradigm of 
choice was an injection of 5 mg/kg PCP twice daily for 7 days which 
selectively reduces dopamine utilization in the prefrontal cortex 
and disrupts schizophrenia-relevant behaviors and stress response 
(Jentsch et al., 1997, 1998a). Later developmental models used an 
injection of 10 mg/kg PCP at postnatal day 7, 9 and 11 to pro-
duce deficits in cognitive functions (prefrontal   cortex-dependent) 
IntroductIon
A common symptom among alcohol-dependent individuals is 
the presence of an executive dysfunction (Kril et al., 1997; Dao-
Castellana et al., 1998). This type of dysfunction is also observed 
in many other psychiatric disorders such as schizophrenia (Lewis 
et al., 2005), depression (Diamond et al., 2004) and obsessive-
compulsive disorder (van den Heuvel et al., 2005). Chronic use of 
alcohol decreases prefrontal cortex volume (De Bellis et al., 2005; 
Chanraud et al., 2007) and even small doses of ethanol in healthy 
volunteers decreases prefrontal cortex excitability (Kahkonen et al., 
2003). At the cellular level, ethanol dose-dependently reduces fir-
ing of prefrontal cortex neurons (Tu et al., 2007) by inhibition of 
NMDA receptor-mediated excitation (Weitlauf and Woodward, 
2008). Previously, we have also found that gene expression of many 
neurotransmitter receptors in the prefrontal cortex correlates with 
the amount of alcohol an individual animal consumes in an operant 
self-administration chamber (Pickering et al., 2007a,b).
In  order  to  study  whether  the  prefrontal  cortex  affects  the 
response to alcohol in dependent individuals, a representative ani-
mal model is required. The most ideal solution would be to use 
‘alcohol-dependent animals’ but this is controversial and difficult 
to achieve. Some have observed signs of dependence (e.g. impul-
sive responding) after self-administration methods (McGregor and 
Gallate, 2004; Belin et al., 2008) while others have employed chronic 
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(Broberg et al., 2008) and GABAergic interneurons (Wang et al., 
2008) in adult animals. Other studies use adolescent animals and 
repeated injections of PCP for one or more weeks. For example, 
repeated exposure to 10 mg/kg PCP impairs Y-maze performance, 
decreases parvalbumin and increases expression of the learning-
dependent transcription factor Arc/Arg 3.1 (Thomsen et al., 2009). 
The 10 mg/kg dose is often used when pharmacologically reversing 
PCP deficits with antipsychotic drugs like quetiapine (Tanibuchi 
et al., 2009), perospirone (Hagiwara et al., 2008) or clozapine 
(Hashimoto et al., 2005). High doses of PCP are neurotoxic (Wang 
and Johnson, 2007) and we wanted to avoid this aspect in our model, 
mainly since we believe that the development of drug dependence 
is a result of chronic neuroadaptations in brain circuitry rather 
than direct ethanol toxicity. Based on this, we chose a lower dose 
of PCP. Repeated injection of 2 mg/kg induces cortical behavio-
ral deficits (Abdul-Monim et al., 2007; Amitai et al., 2007, 2009; 
Amitai and Markou, 2009) and reduces parvalbumin expression 
(Abdul-Monim et al., 2007). Of particular interest is the method of 
Cochran et al. (2003) which produces metabolic hypofunction (i.e. 
reduced glucose utilization in the prefrontal cortex) in adult Long-
Evans rats after injection of 2.58 mg/kg PCP for 5 days. Therefore, 
to overcome the toxicity aspects, we proceeded with the dose of 
2.58 mg/kg PCP for 5 days.
Irrespective  of  the  functional  status  of  the  prefrontal  cor-
tex, evidence suggests an interaction between ethanol and PCP. 
Brunet et al. (1985) found a synergistic effect of ethanol/PCP co- 
administration in terms of the loss of righting reflex while chronic 
pretreatment with ethanol increases binding of radiolabeled PCP 
in the brain of rats (Vadlamani et al., 1982). Both drugs also share 
a similar mechanism of action. PCP is a non-competitive NMDA 
channel antagonist which also has affinity for the sigma1 receptor, 
serotonin 5-HT2 and dopamine D2 receptors (Takahashi et al., 2001; 
Kapur and Seeman, 2002; Seeman et al., 2005). Ethanol also acts to 
antagonize NMDA channel current while potentiating GABAergic 
transmission (Harris et al., 2008). This similar mechanism has been 
demonstrated in substitution experiments in which animals are 
trained to press a lever after injection of, for example, ethanol. 
If another drug is injected and produces the same internal cues 
as ethanol, the animal will press the ‘ethanol lever’. PCP partially 
substitutes for ethanol (Hundt et al., 1998; Bowen and Grant, 1999; 
Green-Jordan and Grant, 2000) however this was not the case in 
all studies (Grant et al., 1992).
Since ethanol and PCP may interact acutely, we began with a 
study of how the combination of both drugs affects dopamine 
release in the nucleus accumbens. A systemic injection of 5 mg/kg 
PCP was chosen for the robust dopamine-elevating effect (150%) 
which was still within the range of that induced by ethanol (Millan 
et al., 1999; Greenslade and Mitchell, 2004). For ethanol, we chose 
to infuse 300 mM directly into the nucleus accumbens. We have, 
in a series of microdialysis articles, demonstrated that ethanol 
infused in this manner acts via glycine receptors and, probably, 
GABAergic feedback neurons to induce dopamine release in the 
nucleus accumbens (Ericson et al., 2003, 2008; Larsson et al., 2005; 
Molander and Soderpalm, 2005). The first question of this study 
was to determine whether systemic PCP injection would influ-
ence this ethanol-induced accumbal dopamine release. Secondly, 
we investigated if the acute interactions between ethanol and PCP 
would change following treatment with 2.58 mg/kg PCP for 5 days. 
Finally, we performed qPCR to verify that our PCP-treated animals 
had prefrontal cortex dysfunction.
MaterIals and Methods
anIMals
Male Wistar rats (n = 54, Taconic, Denmark) weighing 270–300 g, 
were used for the experiments. Upon arrival the rats were housed 
in groups of four in a humidity (65%) and temperature (22°C) 
controlled room on a 12/12-h light/dark cycle (on 07:00 off 19:00), 
with free access to rat food (Lantmännen, Stockholm, Sweden) 
and tap water. Animals were allowed to adapt for at least 7 days to 
the animal maintenance facilities of the department prior to the 
start of the experiments. All experiments were conducted accord-
ing to the Declaration of Helsinki and were approved by the Ethics 
Committee for Animals Experiments (Gothenburg, Sweden).
drugs and cheMIcals
Phencyclidine  hydrochloride  (PCP;  Sigma-Aldrich,  Stockholm, 
Sweden) was dissolved in 0.9% NaCl and administered systemically 
(intraperitoneal, i.p.). Ethanol (Kemetyl AB, Haninge, Sweden) 
was dissolved in Ringer solution and perfused into the nucleus 
accumbens. Ringer solution consisted of (in mmol/l): 140 NaCl, 
1.2 CaCl2, 3.0 KCl, and 1.0 MgCl2.
MIcrodIalysIs technIque
Brain  microdialysis  experiments  were  performed  in  awake  and 
  freely-moving  animals.  Rats  were  anesthetized  by  isofluorane 
(Apoteket AB, Stockholm, Sweden), mounted into a stereotaxic 
instrument (David Kopf Instruments) and put on a heating pad to 
prevent hypothermia during the surgery. Holes were superficially 
drilled for placement of two anchoring screws and one I-shaped 
dialysis probe, custom made in the laboratory. The dialysis probes 
were lowered unilaterally into the nAc (A/P: +1.85, M/L: −1.4, D/V: 
−7.8 relative to bregma; (Paxinos and Watson, 2007). The exposed 
length of the dialysis membrane (active space) was 2 mm. The dialysis 
probes were placed in the core-shell borderline region (suggesting 
that sampling was done in both core and shell of the nAc) and probes 
as well as anchoring screws were fixed to the scull with Harvard 
cement (DAB Dental AB, Gothenburg, Sweden). After surgery, the 
rats were allowed to recover for 2 days before the dialysis experiments 
were initiated. On the experimental day, the sealed inlet and outlet of 
the probes were cut open and connected to a micro-perfusion pump 
(U-864 Syringe Pump, AgnTho’s, Lidingö, Sweden) via a swivel allow-
ing the animal to move around freely. The probes were perfused with 
Ringer solution at a rate of 2 μl/min and dialyzate samples (40 μl) 
were collected every 20 min. The rats were perfused with Ringer 
solution for 1 h in order to obtain a balanced fluid exchange before 
baseline sampling begun. Animals were sacrificed directly after the 
experiment, brains were removed and probe placement was verified 
using a vibroslicer (Campden Instruments).
Biochemical assay
To analyze the dopamine content of the samples, a high-pressure liq-
uid chromatography system was used for the separation and detec-
tion of dopamine as described in (Lido et al., 2009). To identify the 
dopamine peak, an external standard was used containing 2.64 fmol/μl   Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  3
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rapidly removed and the medial prefrontal cortex was dissected 
  according to reference atlases (Heffner et al., 1980; Paxinos and 
Watson, 2007). Tissue samples were snap frozen on a dry ice block 
and stored at −80ºC until further processing. Total RNA extrac-
tion was performed with the RNEasy spin column kit (Qiagen) 
according to manufacturer’s protocols. The TissueRupter (Qiagen) 
was used to ensure complete homogenization of the individual 
samples (approximately 1 min for each sample). RNA was quanti-
fied by absorbance measurement (260-nm wavelength) (BioRad 
spectrophotometer) and 1 μg was used for cDNA synthesis (Qiagen 
kit) which was performed according to standard protocols. This 
kit also contains a DNase treatment step to remove any genomic 
DNA contamination which may have occurred during the RNA 
extraction process. Samples were then diluted to 12.5 ng/μl for 
direct use in the qPCR method.
qPCR and primers
qPCR analysis was performed on the LightCycler 480 real-time 
instrument (Roche) in 96-well plates (Roche). All samples were run 
in duplicate and sometimes this was repeated again if   individual 
of  dopamine. When  at  least  three  consecutive  stable  values  of 
dopamine were obtained (±5%) the first drug was introduced. All 
results are presented as a percent of pre-drug treatment baseline.
Experimental procedure
Daily administration of 2.58 mg/kg PCP (i.p.) or 2 ml/kg vehicle (0.9% 
NaCl) for five consecutive days was followed by 2 days with no injec-
tions. On the experimental day, the animals received local perfusion 
with 300 mM ethanol (continuous administration via the probe from 
the time point indicated in Figure 1 which either was preceded or 
followed by an acute 5 mg/kg PCP systemic injection. Based on pre-
liminary studies of the effects of PCP or ethanol alone (Figure 1C), 
drugs were administered 60 min apart and sampling continued for a 
total of 180 min from administration of the first drug.
qPcr analysIs
Dissection, RNA extraction and cDNA synthesis
In a second group of animals (n = 20), 12 animals were injected 
with 2.58 mg/kg PCP and 8 animals with 0.9% NaCl. At Day 8 
(after 5 days of injection and 2 days of recovery), brains were 
Figure 1 | In vivo microdialysis measuring dopamine release in the 
nucleus accumbens of awake, freely-moving animals. (A) Systemic injection 
of 5 mg/kg PCP-induced dopamine release but blocked the dopamine-elevating 
effects of a local 300 mM ethanol infusion. No differences were observed when 
animals were pretreated for 5 days with 2.58 mg/kg PCP . (B) 300 mM ethanol 
infusion produced the expected dopamine increase and 5 mg/kg PCP injection 
led to a potentiated dopamine response compared to the first experiment. 
Again, no effect of PCP pretreatment was observed. (C) PCP injection (5 mg/kg) 
alone produced a sustained dopamine release from 40 to 120 min. Three 
hundred millimolar ethanol infusion into the nucleus accumbens produced a 
peak dopamine release after 40 min which then fell to levels close to baseline by 
60 min. Based on these results, drugs in the combination experiments were 
administered 60 min after the each other. (D) Comparison of the relative 
dopamine release stimulated by PCP injection. When ethanol was administered 
first, the PCP-induced dopamine elevation was greater than PCP alone (t-test, 
*p < 0.05). (e) Comparison of the relative dopamine release stimulated by 
ethanol infusion. Ethanol induced significantly less dopamine release when the 
infusion was proceeded by PCP injection (t-test, *p < 0.05).Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  4
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Statistical analysis
Microdialysis data was compared by two-way repeated measures 
ANOVA with factor Drug to compare Saline vs PCP effects and fac-
tor Time to denote the actual changes in dopamine release induced 
by the drugs. An unpaired t-test was used to compare relative PCP-
induced dopamine release. A significance level of p = 0.05 was used 
for all analyses in this experiment.
Calculation  of  the  relative  dopamine  release  per  drug 
(Figures 1D,E) were calculated as follows. Irrespective of drug, 
the peak dopamine effect was observed 40 min after administra-
tion (Figure 1C). As such, dopamine release for the first drug was 
defined as the dopamine value at t = 40 divided by the baseline 
value. Dopamine release of the second drug was the dopamine 
value at t = 100 divided by the value at t = 60.
results
effects of adMInIstratIon order on nucleus accuMbens 
doPaMIne release
Dopamine release in the nucleus accumbens was measured during 
injection/infusion of either PCP or ethanol. Both administration 
orders were tested in order to assess the pharmacological interac-
tion between the two compounds. Probe placement was verified by 
sectioning (VibroSlice, Camden Instruments) and only correctly-
placed probes positioned in the nucleus accumbens were included 
in this study. Starting with a two-way repeated measures ANOVA of 
the entire microdialysis experiment, the drugs significantly changed 
dopamine release over time when either PCP (F = 13.8; p < 0.0001) 
or ethanol (F = 25.1; p < 0.0001) were administered first.
PCP followed by local accumbal administration of ethanol
A two-way repeated measures ANOVA illustrated that injection of 
5 mg/kg PCP significantly induced dopamine release in the nucleus 
accumbens (F = 22.4; p < 0.0001: Time −20 to 60 min). However, 
infusion of 300 mM ethanol into the nucleus accumbens after this 
PCP injection failed to induce dopamine release (F = 0.367; p = 0.869: 
Time 60 to 180 min) (Figure 1A). To illustrate this blockade of ethanol-
  induced dopamine release by PCP, we re-calculated a percent of baseline 
value relative to the 60 min point (Figure 1E). When PCP was infused 
first, ethanol induced significantly less dopamine release (p = 0.0119) 
compared to normal ethanol induced dopamine release.
Accumbal ethanol infusion followed by PCP injection
Ethanol infusion induced dopamine release in the nucleus accumbens 
(F = 7.87; p < 0.0001: Time −20 to 60 min) (Figure 1B). Subsequent 
injection of 5 mg/kg PCP also induced the release of dopamine 
(F = 5.71; p = 0002: Time 60 to 180 min) and the Interaction factor 
was also significantly different (F = 2.63; p = 0.0304). To compare 
the relative PCP-induced dopamine release, we re-calculated a 
percent of baseline value relative to the 60 min point (Figure 1D). 
When ethanol was infused first, PCP induced a greater relative 
dopamine release in the nucleus accumbens (p = 0.0334) than PCP 
injection alone, indicating a synergistic action between ethanol and 
PCP which was dependent on the order of administration.
effects of 5-day PcP PretreatMent
In the second part of this experiment, we investigated whether pre-
treatment with PCP for 5 days (i.e. prefrontal cortex hypofunction) 
would change the individual response to ethanol or PCP.
values did not concur. The PCR reaction was based on the standard 
protocol for the Hot Start Taq polymerase enzyme kit (Qiagen) 
with SYBR green as the fluorescent reporter. The 20 μl sample 
volume consisted of 10 μl 2 ×  SYBR Green Master mix (Qiagen), 
6 μl RNAse free water, 2 μl primer and 2 μl cDNA. All primers 
were pre-designed QuantiTect Primer Assays from Qiagen which 
unfortunately does not disclose the actual sequence of the primer 
pair but rather gives an approximate gene location on their website. 
These primers are pre-optimized to give roughly the same PCR 
efficiency (Table 1) for eventual inter-gene comparisons and also 
allow for the same PCR reaction conditions for the whole experi-
ment. A total of 45 cycles (15-s denaturation at 94°C, 20-s anneal-
ing at 55°C, 20-s extension at 72°C) were run for each primer. A 
melting curve analysis was performed after each PCR program 
to ensure that a single product was produced in each sample. 
Samples with primer dimers/multiple products were excluded 
and re-analyzed.
Normalization factors, reference genes and analysis
Proper normalization of PCR data and the use of multiple refer-
ence genes are critical for the accurate analysis of gene expres-
sion (Vandesompele et al., 2002). The reference genes beta-actin, 
GAPDH, RPL19 and SDHA were analyzed in this experiment. 
Primer  efficiencies  were  calculated  using  the  assumption-free 
method of Ramakers and colleagues which uses a linear regression 
of the fluorescence curve (linregPCR v11.1 software) to estimate the 
efficiency for each run (Ramakers et al., 2003; Ruijter et al., 2009). Ct 
values for each sample were calculated with the Light Cycler analysis 
module provided with the equipment (Roche). To compare Saline 
and PCP-treated animals, we used the REST2008 gene expression 
analysis program (Pfaffl et al., 2002). Using the calculated primer 
efficiencies and Ct values, the program performs 5000 iterations 
to compare whether there is a difference in expression between the 
groups. This also takes into account the reference genes. Expression 
values from this program are a ratio such that values above 1 denote 
an upregulation of gene expression in the treated group while values 
less than 1 indicate a downregulation.
Table 1 | effects of 5 day 2.58 mg/kg PCP injections on the mrNA 
expression of genes relevant for glucose utilization and interneuron 
prevalence. Expression ratio of 1 indicates no difference in expression 
between PCP (n = 12) and Saline (n = 7) groups. Ratios less than 1 indicate 
downregulation. Since P(H1) was greater than 0.05 for all genes, PCP at this 
dose, did not significantly affect gene expression. Reaction efficiency is 
listed as a control for the Qiagen primer assays which are all optimized to 
95% efficiency.
gene  reaction efficiency  expression ratio  P(H1)
SLC2A1/GLUT1  94.6%  1.038  0.683
SLC2A3/GLUT3  94.7%  1.088  0.150
SLC16A7/MCT-2  94.8%  1.032  0.728
SLC1A2/GLT-1  95.1%  0.838  0.120
SLC1A3/GLAST  95.1%  1.038  0.677
Arc/Arg3.1  95.3%  1.044  0.845
SLC6A1/GAT-1  94.9%  1.089  0.262
Synaptophysin  94.9%  1.022  0.678
Parvalbumin  95.3%  0.735  0.192Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  5
Pickering et al.  Ethanol and phencyclidine’s dopaminergic interactions
on the order of administration of the two drugs. Intraperitoneal 
injection of 5 mg/kg PCP increased accumbal dopamine release but 
blocked any actions of a 300 mM local infusion of ethanol directly 
into the nucleus accumbens. When ethanol was infused first, the 
expected dopamine release was produced but this potentiated sub-
sequent PCP-induced dopamine release. Pretreatment for 5 days 
with 2.58 mg/kg PCP did not affect the response to ethanol or PCP 
and a further study of the gene expression of markers normally 
affected by PCP treatment (e.g. GABAergic markers, immediate 
early genes, etc.) did not provide any evidence of prefrontal cortex 
hypofunction in these animals after exposure to this low and non-
toxic PCP dose.
As mentioned previously, an interaction between ethanol and 
PCP was expected from previous studies (Brunet et al., 1985) 
but this is the first time an interaction has been demonstrated at 
the level of dopamine release in the nucleus accumbens. Starting 
with ethanol’s mechanism of action following local accumbal 
infusion, our theory proposes that ethanol stimulates inhibitory 
glycine receptors on GABAergic feedback neurons in the nucleus 
accumbens and this disinhibition releases an inhibitory ‘brake’ 
which tonically prevents activation of dopaminergic neurons in 
the ventral tegmental area (Soderpalm et al., 2009). An explana-
tion of how a systemic injection of PCP induces dopamine release 
is complex given this compound’s actions at the sigma1 recep-
tor (Minabe et al., 1999) and other non-NMDA targets (Hundt 
et al., 1998; Svensson, 2000; Takahashi et al., 2001). A lesion of 
the prefrontal cortex prevents PCP-induced locomotor stimula-
tion and nucleus accumbens dopamine release, illustrating the 
necessity of prefrontal cortex projections for PCP’s effects (Jentsch 
et al., 1998b). The actual mechanism of PCP may, however, be 
explained by changes in firing patterns of nucleus accumbens 
GABAergic neurons. Glutamatergic inputs from the prefrontal 
cortex, hippocampus and other regions regulate the up and down 
Nucleus accumbens dopamine release
There was no difference in baseline dopamine amount (p = 0.995) 
between PCP and Saline-treated groups (Figure 1A, inset) A two-
way repeated measures ANOVA was performed (PCP vs Saline) to 
determine whether pretreatment affected the release of dopamine. 
When PCP was administered first (Figure 1A), there was no 
between-group difference (Factor Drug: F = 0.00606; p = 0.939) 
and with no significant Interaction (F = 0.256; p = 0.989). When 
ethanol was infused first (Figure 1B), there was also no differ-
ence between the PCP pretreatment and Saline groups (Factor 
Drug: F = 0.00838; p = 0.928) with no significant Interaction 
(F = 1.004; p = 0.442).
Changes in mPFC gene expression following 5-day PCP pretreatment
To verify that injection of 2.58 mg/kg PCP for 5 days would pro-
duce a hypofunction, we dissected the medial prefrontal cortex 
and analyzed mRNA expression of several key energy transporters 
or components of the GABAergic system. Of the four reference 
genes analyzed, RPL19 was excluded because it was differentially 
regulated in the PCP group. One animal in the Saline group was 
excluded due to poor extraction yield and subsequent difficul-
ties with cDNA synthesis. Pretreatment with PCP did not change 
the mRNA expression of any gene tested (Table 1) although the 
glutamate transporter SLC1A2/GLT-1 had the strongest trend to 
significance (p = 0.120). A boxplot of the results produced by the 
REST2008 program (Figure 2) indicated a wider distribution of 
expression ratios for Arc and parvalbumin which could suggest sub-
grouping in the population with respect to PCP treatment effect.
dIscussIon
With respect to the induction of dopamine release in the nucleus 
accumbens, a clear interaction between ethanol and PCP was dem-
onstrated in this study. This interaction, however, was dependent 
Figure 2 | Boxplot of differential gene expression generated by the reST2008 software. The considerable variability in Arc and parvalbumin compared to other 
genes suggests PCP-induced dysfunction in some but not all individuals.Frontiers in Behavioral Neuroscience  www.frontiersin.org  June 2010  | Volume 4  | Article 32  |  6
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(Pellerin et al., 2007). Since PCP is an NMDA antagonist, adap-
tive changes similar to our previous study (Pickering et al., 2006) 
could occur to counteract excessive glutamate release. Again, PCP 
pretreatment did not significantly change gene expression of these 
glutamate transporters although GLT-1 did have the strongest 
trend to significance (p = 0.12) of all the genes analyzed. A similar 
lack of effect was observed for the transcription factor Arc (Arg 
3.1) despite a clear PCP-induced increase of this in other studies 
(Thomsen et al., 2009). We therefore must conclude that treat-
ment for 5 days with 2.58 mg/kg PCP did not induce prefrontal 
cortex hypofunction.
The  absence  of  a  PCP  effect  in  our  animals  compared  to 
Cochran and colleagues was probably due to the low dose of 
2.58 mg/kg PCP but this could also be explained by strain differ-
ences or animal age. It is plausible that a subgroup of animals may 
have had a hypofunction since the distribution of between-group 
expression for Arc and parvalbumin was much larger than that 
of other genes (Figure2). Nonetheless, a review of the literature 
indicates several ways to decrease the proportion of non-responder 
animals. We have chosen adult outbred Wistar rats for this study 
because we have characterized the effects of ethanol in these ani-
mals. Other protocols with demonstrable PCP-induced hypofunc-
tion use Long-Evans rats (Cochran et al., 2003) or C57BL/6J mice 
(Thomsen et al., 2009). We may also have failed to achieve hypo-
function because our animals were too old although some studies 
suggest increased susceptibility to PCP-induced neurotoxicity with 
age (Farber et al., 1995). PCP may be injected on postnatal day 7, 
9 and 11 to produce a subsequent hypofunction in adult animals 
(Broberg et al., 2008; Wang et al., 2008). Cochran and colleagues 
used animals of a weight (180–220 g) corresponding roughly with 
adolescence in rodents, an age often chosen for the study of devel-
opmental effects since several brain areas (e.g. prefrontal cortex) 
are not yet fully developed and clinical studies often demonstrate 
the increased use of drugs at this age (Doremus-Fitzwater et al., 
2009). By fine-tuning the age, strain and dose factors, it will be 
possible to produce a prefrontal cortex dysfunction in rats. But it 
was clear from the qPCR results in this study that a higher dose 
of PCP will be required.
Overall, we have demonstrated that ethanol and PCP interact 
with respect to the induction of dopamine release in the nucleus 
accumbens. This acute and order-dependent effect suggests further 
study of this drug combination with respect to local infusion stud-
ies but it also warns for potential difficulties in the interpretation of 
results in animals with PCP-induced prefrontal cortex dysfunction. In 
particular, we demonstrated the inability of the 2.58 mg/kg PCP dose 
to induce a measurable prefrontal cortex dysfunction, again illustrat-
ing the importance of a careful selection of animal strain, age, dose 
and administration pattern when performing studies of this type.
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states of nucleus accumbens neurons since electrical stimulation 
of these regions will produce an EPSP (O’Donnell and Grace, 
1995). In particular, these afferents from the hippocampus will, 
upon stimulation, shift nucleus accumbens neurons to a depolar-
ized ‘up’ state. Since these accumbal neurons are GABAergic, the 
net result will be an inhibition of target regions of these feedback 
neurons (e.g. the ventral tegmental area) (O’Donnell and Grace, 
1998). Acute systemic injection of PCP blocks the transition of 
nucleus accumbens GABAergic neurons from the inactive ‘down’ 
state to the depolarized ‘up’ state which reduces the chance of 
firing, thus removing the strong inhibition of ventral tegmental 
area dopamine neurons (O’Donnell and Grace, 1998). This is how 
we propose that our order effect can be explained. When PCP is 
administered first, GABAergic feedback neurons are disinhibited 
such that the local action of ethanol on these neurons cannot have 
an increased effect with respect to dopamine release. However, 
when ethanol is administered first, GABAergic feedback neurons 
can release dopamine as usual and systemic PCP can still affect the 
activity of other brain regions. The change in neurotransmission 
already started by ethanol somehow potentiated the dopamine-
releasing ability of PCP. Therefore, a further investigation of this 
interaction is important in order to determine whether prefrontal 
cortex dysfunction will affect the response to ethanol.
The acute interaction of PCP and ethanol complicates the ques-
tion of whether PCP-induced cortical hypofunction affects the 
response to ethanol. Repeated PCP treatment suggests a decrease 
in dopamine utilization that is selective to the prefrontal cortex 
and not the nucleus accumbens (Jentsch et al., 1997). It is there-
fore conceivable that the dopamine response of ethanol following 
accumbal infusion may not change following PCP treatment. This 
was, in fact, what we observed in this study. However, we cannot 
make this conclusion since a clear PCP-induced prefrontal cortex 
dysfunction could not be demonstrated. In the literature, PCP 
causes a selective decrease in GABAergic chandelier neurons in 
the prefrontal cortex (Wang et al., 2008). These parvalbumin-
positive neurons can be labeled by immunohistochemistry against 
the GABA transporter GAT-1 (SLC6A1) which visualizes a series 
of synaptic sites located along the axon of pyramidal neurons 
(Hardwick et al., 2005). These chandelier neurons strongly inhibit 
pyramidal neuron activity (Lewis et al., 1999) so a selective PCP-
induced decrease of these neurons should increase the glutama-
tergic output from the prefrontal cortex to limbic or striatal 
areas. We pretreated another group of animals and extracted the 
medial prefrontal cortex for gene expression analysis via qPCR. 
Using this method, no PCP-induced changes were observed for 
GAT-1 (SLC6A1), synaptophysin or parvalbumin. Cochran et al. 
(2003) defined prefrontal cortex hypofunction by a reduction 
in glucose utilization. Changes in glucose utilization were esti-
mated by analysis of mRNA levels of the glucose transporters 
Glut1 (SLC2A1) and Glut3 (SLC2A3). In line with the potential 
role of lactate as an energy source for neurons following activa-
tion (Pellerin et al., 2007), we also measured expression of the 
monocarboxylate transporter MCT2 (SLC16A7). PCP did not 
significantly affect any of these energy transporters. The high-
affinity glial-specific glutamate transporters GLT-1 (SLC1A2) and 
GLAST (SLC1A3) (Shigeri et al., 2004) are also integral in the 
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